Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
about
HIV-1 neutralizing antibodies: understanding nature's pathwaysAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsBiologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positioChimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cellsAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloBinding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE virusesEngineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsStrategies to guide the antibody affinity maturation processAntigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategyReplication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Inhibition of HIV-1 entry by antibodies: potential viral and cellular targetsAchieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Problems and emerging approaches in HIV/AIDS vaccine development.A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction.Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras.Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.
P2860
Q27000480-58E0F023-FDD6-41C0-A5A2-944DD8B35DDDQ27489000-576CE12C-44EC-4577-A5FB-F3986DB39B48Q28732438-7BC96E94-38C3-48EF-9F28-5B3C3AE9D8B6Q29619015-6F6AE53B-F8AE-4798-A2CE-62B25A74DD18Q30379200-7049123E-E5E9-4B46-BB84-38D4A683DC11Q30381447-0BA28E3B-95C4-48E3-BE4D-0FD0303880B5Q33571825-727A8069-C53D-4EE6-AE76-3AD8B0D5DC32Q33601372-F8FBE3F3-A35F-4973-B09E-C25ED6F5FF29Q33717477-89306CA4-E7D5-4096-B721-4859DFF5B2A2Q33724169-0176DB32-0E3A-4B9F-A519-08C1775D41A6Q33737723-3DB27E8C-597E-4E4D-B798-5907E2311928Q33780524-8C3D3932-4E9B-4802-94D0-9EB7C56DB30FQ33883887-BBF13AFA-E83A-474F-89ED-030D27C00934Q33911809-0399FDC7-A38D-4231-8124-6F4404BAD430Q34120088-0598C009-0080-4A43-AD83-13549CFE23F5Q34552313-F40C4ACA-8E96-4851-B0DB-04C1EA2BD36DQ34583767-40819951-86F6-43C7-9EA5-E1639695AFBDQ34658136-7599C4D1-9929-4C39-A8AE-D946756F7ECBQ34796885-A7EC7131-AEC8-41AC-9726-4F133B4AE46CQ35024202-1448E919-B019-4659-BC4A-6CB6C36223A5Q35077716-275B409F-0E56-4994-801A-EFBDFC751095Q35110976-C37ABAA3-D817-4FB6-9A60-61E44EC86D81Q35582579-3CA9AD11-6A5D-437D-BAB6-9D644614A022Q35666057-F4E850F0-DBD7-4CD3-BEB8-CE7325875159Q35677724-3E88FEE1-C6D3-4DE7-90DB-0AF80EFE63E4Q35685300-D6C39C48-2897-43C2-AB10-F2FDDA893A1CQ35785338-FCE58D9C-C9C9-4258-BFC7-A7591052291BQ36098903-585B8455-5E0C-4428-9FB0-1C10185A4E9BQ36103090-3401016A-487E-4FB6-A1C8-3BEC078F293CQ36131738-DD861146-EE35-47E0-9B95-C8A63B8C1A78Q36149102-6976EFA5-7652-458E-AE0C-09E57DE0F6A0Q36600380-B7C9D829-79E6-49F1-8033-D2767FBDD94FQ36631937-C87FF2E7-B297-4ABF-86C1-E69884622FC8Q36702114-DE30E62A-79EE-4DF0-808D-60F8BFA67A82Q36758574-34370743-4950-4060-8433-BC3922BF0755Q36926701-1AE056A0-ED6D-4D0B-A71B-3941BF245BF6Q36954218-4F60BED4-3503-49B3-B4BB-ACC3A9E1C053Q37059723-6690741A-517A-49AD-B9DE-ABEF8FAD87C1Q37092741-9DBD8C29-7747-4244-B278-AF85A38E619BQ37123584-C0A80EAA-8EBC-4394-AB4D-D64BD03FBFA2
P2860
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Changes in the immunogenic pro ...... he second hypervariable region
@ast
Changes in the immunogenic pro ...... he second hypervariable region
@en
Changes in the immunogenic pro ...... he second hypervariable region
@nl
type
label
Changes in the immunogenic pro ...... he second hypervariable region
@ast
Changes in the immunogenic pro ...... he second hypervariable region
@en
Changes in the immunogenic pro ...... he second hypervariable region
@nl
prefLabel
Changes in the immunogenic pro ...... he second hypervariable region
@ast
Changes in the immunogenic pro ...... he second hypervariable region
@en
Changes in the immunogenic pro ...... he second hypervariable region
@nl
P2093
P2860
P1433
P1476
Changes in the immunogenic pro ...... he second hypervariable region
@en
P2093
Indresh K Srivastava
Keating VanDorsten
Leonidas Stamatatos
Susan W Barnett
P2860
P304
P356
10.1128/JVI.77.4.2310-2320.2003
P407
P577
2003-02-01T00:00:00Z